Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC)

被引：3
|
作者：
Ardizzoni, Andrea
Razis, Evangelia
Lichinitser, Mikhail
Yilmaz, Ugur
Grigorescu, Alexandru C.
Morero, Jose Luis
Skrickova, Jana
Cervantes, Guadalupe
Gottfried, Maya
Van Meerbeeck, Jan
机构：
[1] Univ Parma, Parma, Italy
[2] Hygeia Hosp, Athens, Greece
[3] NN Blochin Russian Oncol Res Ctr, Moscow, Russia
[4] Dokuz Eylu Univ, Med Fac, Izmir, Turkey
[5] Bucharest Oncol Inst, Bucharest, Romania
[6] Hosp Maria Ferrer, Buenos Aires, DF, Argentina
[7] Univ Hosp Brno, Brno, Czech Republic
[8] ISSSTE, Hosp Noviembre Ctr Medico, Mexico City, DF, Mexico
[9] Meir Sapir Med Ctr, Kefar Sava, Israel
[10] Univ Hosp, Ghent, Belgium
来源：
JOURNAL OF THORACIC ONCOLOGY | 2007年 / 2卷 / 08期
关键词：
D O I：
10.1097/01.JTO.0000283158.26734.bc
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S342 / S342
页数：1
相关论文
共 50 条
  • [1] Erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): interim results from the European subpopulation of the open-label TRUST study
    Smit, E.
    Reck, M.
    Krzakowski, M.
    Gridelli, C.
    Curescu, S.
    Berzinec, P.
    Barata, F.
    McDermott, R.
    Jovanovic, D.
    Magyarlo, P.
    EJC SUPPLEMENTS, 2007, 5 (04): : 359 - 359
  • [2] Biomarker analyses from an open-label study of erlotinib in advanced non-small-cell lung cancer (NSCLC)
    van Zandwijk, N.
    Su, W.
    Rooneem, R.
    MehilDc, B.
    Franke, F. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] The global TRUST study of erlotinib in advanced non-small-cell lung cancer (NSCLC)
    Groen, H.
    Arrieta, O. G.
    Riska, H.
    Horwood, K.
    Mali, P.
    Reck, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Second-line erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): Results from a large, open-label study
    Crino, L.
    Boyer, M.
    Eberhardt, W. E.
    Baliko, Z.
    Smit, E. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Interim safety results from the East/South East (E/SE) Asian subgroup of the open-label TRUST (TaRceva lUng cancer Survival Treatment) study of erlotinib for advanced non-small-cell lung cancer (NSCLC)
    Park, Keunchil
    Lee, Jong-Seok
    Wu Yi-Long
    Zhang Li
    Cheng, Ashley
    Siu-Kie-Au, Joseph
    Voravud, Narin
    Muthalib, Abdul
    Wahid, Mohd Ibrahim A.
    Yang, Chih-Hsin
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S464 - S465
  • [6] CLINICAL OUTCOMES WITH ERLOTINIB IN RELATION TO BIOMARKER STATUS: ANALYSES FROM THE OPEN-LABEL TRUST STUDY IN ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Pirker, R.
    Su, W.
    Rooneem, R.
    Mehic, B.
    Franke, F.
    ANNALS OF ONCOLOGY, 2008, 19 : 100 - 101
  • [7] SAFETY AND EFFICACY OF ERLOTINIB IN NON-SMALL-CELL LUNG CANCER (NSCLC) IN ISRAEL: INTERIM ANALYSIS FROM THE TRUST STUDY
    Gottfried, M.
    Levitt, M.
    Wollner, M.
    Dudnik, J.
    Peylan-Ramu, N.
    Flex, D.
    Barak, F.
    Biran, H.
    Cyjon, A.
    Merimsky, O.
    ANNALS OF ONCOLOGY, 2008, 19 : 103 - 103
  • [8] Erlotinib in non-small cell lung cancer (NSCLC): Interim safety analysis of the TRUST study
    Gatzemeier, U.
    Ardizzoni, A.
    Horwood, K.
    van Meerbeeck, J.
    Magyar, P.
    Gottfried, M.
    Arrieta, O.
    Krzakowski, M.
    Franke, F.
    van Zandwijk, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] SUBGROUP ANALYSES OF EFFICACY IN THE GLOBAL TRUST STUDY OF ERLOTINIB IN NON-SMALL-CELL LUNG CANCER (NSCLC)
    Bosquee, L.
    Franke, A.
    Jovanovic, D.
    Pirker, R.
    Scagliotti, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 99 - 100
  • [10] Efficacy of erlotinib in patients with advanced Non-small-cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST study
    Boyer, Michael
    Horwood, Keith
    Pavlakis, Nick
    De Souza, Paul
    Millward, Michael
    Stein, Brian
    Johnston, Michael
    Abell, Fiona
    Rischin, Danny
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 (03) : 248 - 254
12345